These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 6230226

  • 1. Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues.
    Seibert G, Limbert M, Klesel N.
    Eur J Clin Microbiol; 1983 Dec; 2(6):548-53. PubMed ID: 6230226
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A, Ullmann U.
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():33-8. PubMed ID: 6238931
    [Abstract] [Full Text] [Related]

  • 4. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A, Phillips I.
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro and in vivo activity of DL-8280, a new oxazine derivative.
    Sato K, Matsuura Y, Inoue M, Une T, Osada Y, Ogawa H, Mitsuhashi S.
    Antimicrob Agents Chemother; 1982 Oct; 22(4):548-53. PubMed ID: 6960805
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.
    Muytjens HL, van der Ros-van de Repe J, van Veldhuizen G.
    Antimicrob Agents Chemother; 1983 Aug; 24(2):302-4. PubMed ID: 6227281
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.
    Chin NX, Neu HC.
    Antimicrob Agents Chemother; 1984 Mar; 25(3):319-26. PubMed ID: 6232895
    [Abstract] [Full Text] [Related]

  • 13. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin.
    Speciale A, Stefani S, Caccamo F, Nicolosi VM, Nicoletti G.
    Chemioterapia; 1987 Feb; 6(1):17-22. PubMed ID: 3470153
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vitro evaluation of A-56619 and A-56620, two new quinolones.
    Barry AL, Thornsberry C, Jones RN.
    Antimicrob Agents Chemother; 1986 Jan; 29(1):40-3. PubMed ID: 2942099
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
    King A, Shannon K, Phillips I.
    J Antimicrob Chemother; 1984 Apr; 13(4):325-31. PubMed ID: 6233249
    [Abstract] [Full Text] [Related]

  • 20. Antibacterial activity of ofloxacin and its mode of action.
    Sato K, Inoue Y, Fujii T, Aoyama H, Mitsuhashi S.
    Infection; 1986 Apr; 14 Suppl 4():S226-30. PubMed ID: 3028966
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.